title: Three-year safety and efficacy of treating all-comers with newer-generation Resolute Integrity or PROMUS Element stents in the randomised DUTCH PEERS (TWENTE II) trial.
abstract: OBJECTIVE
  The aim of this report was to assess the three-year safety and efficacy of implanting newer-generation Resolute Integrity zotarolimus-eluting stents (ZES) versus PROMUS Element everolimus-eluting stents (EES) in all-comers.
  
  
  RESULTS
  In the randomised, multicentre, investigator-initiated DUTCH PEERS trial, a total of 1,811 all-comers were 1:1 randomly assigned to treatment with ZES versus EES. A total of 1,293 patients (72%) were treated for complex lesions and 455 patients (25%) were treated for multiple lesions. The primary endpoint target vessel failure (TVF) is a composite of cardiac death, target vessel-related myocardial infarction or target vessel revascularisation. Adverse clinical events were independently adjudicated. Three-year follow-up data were obtained in 1,807 patients (99.8%, four withdrawals). Both the ZES and EES groups showed favourable outcomes with a similar incidence of TVF (10.7% vs. 10.3%; pLog-rank=0.77) and the individual components thereof: cardiac death (3.2% vs. 3.1%; pLog-rank=0.87), target vessel-related myocardial infarction (2.8% vs. 2.2%; pLog-rank=0.44) and target vessel revascularisation (6.0% vs. 6.2%; pLog-rank=0.87). In addition, the incidence of definite or probable stent thrombosis was similar for patients treated with ZES versus EES (1.4% vs. 1.1%; pLog-rank=0.66).
  
  
  CONCLUSIONS
  The safety and efficacy of treating all-comers with newer-generation Resolute Integrity and PROMUS Element stents was found to be extended up to three years.
authors.affiliation: Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, the Netherlands.
authors.forename: Liefke C
authors.initials: LC
authors.lastname: van der Heijden
authors.forename: Marlies M
authors.initials: MM
authors.lastname: Kok
authors.forename: Marije M
authors.initials: MM
authors.lastname: Löwik
authors.forename: Peter W
authors.initials: PW
authors.lastname: Danse
authors.forename: Gillian A J
authors.initials: GAJ
authors.lastname: Jessurun
authors.forename: Raymond W M
authors.initials: RWM
authors.lastname: Hautvast
authors.forename: K Gert
authors.initials: KG
authors.lastname: van Houwelingen
authors.forename: Martin G
authors.initials: MG
authors.lastname: Stoel
authors.forename: Marc
authors.initials: M
authors.lastname: Hartmann
authors.forename: Gerard C
authors.initials: GC
authors.lastname: Linssen
authors.forename: Carine J M
authors.initials: CJM
authors.lastname: Doggen
authors.forename: Clemens
authors.initials: C
authors.lastname: von Birgelen
mesh_terms: D054855:Drug-Eluting Stents / Q000706:statistics & numerical data*; D005500:Follow-Up Studies; D006801:Humans; D062645:Percutaneous Coronary Intervention / Q000295:instrumentation*